Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a Locations section with Virginia and its details; removed the HHS Vulnerability Disclosure and Virginia Locations, and updated to Revision: v3.3.3.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page now shows 'Results Submitted' instead of 'No Results Posted', indicating that trial results have been submitted.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedFooter revision tag updated from v3.2.0 to v3.3.2 with no changes to study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedA government funding status notice previously shown on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedStudy Completion (Estimated) is now listed as 2031-01, and the Study Record Dates show a new update (Last Update Posted 2025-03-27) with QC criteria updates.SummaryDifference0.5%

- Check92 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.